MIRVASO® (brimonidine) topical gel, 0.33%* is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.
MIRVASO Topical Gel is a temporary treatment for facial redness
MIRVASO Topical Gel may dramatically reduce your symptoms, but it won’t prevent or cure facial redness. Your redness will return after the effect of MIRVASO Topical Gel wears off.
MIRVASO Topical Gel is available in the MIRVASO Topical Gel Pump
The delivery system of the MIRVASO Topical Gel pump gives a consistent dose at each use.
Exposure to triggers could make your symptoms worse
Avoid your triggers, even if you are using MIRVASO Topical Gel as directed.
Uses / Instructions
Apply a pea-sized amount to each of the areas affeced by Rosacea ONE time daily
See patient information leaflet for full details.
MIRVASO Topical Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure.
MIRVASO Topical Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease.
Serious adverse reactions following accidental ingestion of MIRVASO Topical Gel by children have been reported.
Keep MIRVASO Topical Gel out of reach of children.
Not for oral, ophthalmic, or intravaginal use.
In clinical trials, about 10% of subjects reported worsening of redness while using MIRVASO Topical Gel.
In every case this side effect was temporary and went away on its own.
One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.
One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol (E1520).
Other ingredients: Carbomer, Methylparahydroxybenzoate (E218), Phenoxyethanol, Glycerol, Titanium dioxide, Propylene glycol (E1520), Sodium hydroxide, Purified water